2022
DOI: 10.1007/s40261-022-01168-0
|View full text |Cite
|
Sign up to set email alerts
|

Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…The treatment of cancer patients is a notable therapeutic application. Immunotherapy with anti-epidermal growth factor receptor (EGFR) (cetuximab) [21,22], anti-CD20 (rituximab) [23,24], anti-vascular endothelial growth factor (bevacizumab) [25][26][27], or anti-programmed cell death protein-1 (PD1) (ipilimumab) [28][29][30] is employed to combat specific oncological diseases.…”
Section: Introductionmentioning
confidence: 99%
“…The treatment of cancer patients is a notable therapeutic application. Immunotherapy with anti-epidermal growth factor receptor (EGFR) (cetuximab) [21,22], anti-CD20 (rituximab) [23,24], anti-vascular endothelial growth factor (bevacizumab) [25][26][27], or anti-programmed cell death protein-1 (PD1) (ipilimumab) [28][29][30] is employed to combat specific oncological diseases.…”
Section: Introductionmentioning
confidence: 99%